deltatrials
Completed PHASE1 INTERVENTIONAL 3-arm NCT03349281

Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL

A Phase I Trial of Pevonedistat in Combination With Induction Chemotherapy for Adolescent and Young Adults With Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin Lymphoma

Sponsor: Julio Barredo, MD

Conditions Refractory Acute Lymphoblastic Leukemia Relapsed Acute Lymphoblastic Leukemia
Interventions Cytarabine Dexamethasone Doxorubicin Hydrocortisone Methotrexate PEG-asparaginase Pevonedistat Vincristine
Updated 17 times since 2017 Last updated: Oct 19, 2022 Started: Mar 25, 2019 Primary completion: Aug 11, 2021 Completion: Oct 12, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Refractory Acute Lymphoblastic Leukemia and Relapsed Acute Lymphoblastic Leukemia and is currently completed. Julio Barredo, MD leads this study, which shows 17 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Dec 2018 · 5 months · monthly snapshot~Dec 2018 – ~Mar 2019 · 3 months · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshot~Jun 2019 – ~Dec 2019 · 6 months · monthly snapshot~Dec 2019 – ~May 2020 · 5 months · monthly snapshot~May 2020 – ~Dec 2020 · 7 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Sep 2021 · 6 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Nov 2022 · 11 months · monthly snapshot~Nov 2022 – ~Jul 2024 · 20 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Nov 2022 — Jul 2024 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  4. Dec 2021 — Nov 2022 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  5. Sep 2021 — Dec 2021 [monthly]

    Recruiting PHASE1

▶ Show 12 earlier versions

  1. Mar 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  2. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE1

  3. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  4. May 2020 — Dec 2020 [monthly]

    Recruiting PHASE1

  5. Dec 2019 — May 2020 [monthly]

    Recruiting PHASE1

  6. Jun 2019 — Dec 2019 [monthly]

    Recruiting PHASE1

  7. Apr 2019 — Jun 2019 [monthly]

    Recruiting PHASE1

  8. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE1

  9. Dec 2018 — Mar 2019 [monthly]

    Recruiting PHASE1

  10. Jul 2018 — Dec 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  11. Jun 2018 — Jul 2018 [monthly]

    Not Yet Recruiting PHASE1

  12. Dec 2017 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Julio Barredo, MD
  • Takeda
Data source: University of Miami

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations